1h Free Analyst Time
The Short Bowel Syndrome Market grew from USD 818.23 million in 2023 to USD 966.42 million in 2024. It is expected to continue growing at a CAGR of 19.14%, reaching USD 2.78 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Short Bowel Syndrome (SBS) represents a significant area in medical research and treatment, defined as a malabsorption disorder caused by the surgical removal of a large portion of the small intestine, congenital defect, or disease impact resulting in significant nutrient assimilation issues. The necessity of efficiently managing SBS is underscored by its debilitating nature, involving complex treatment requiring specialized nutrition support and medication, thus creating robust demand in the healthcare market. The application of SBS treatments primarily revolves around hospital settings, specialized gastroenterology clinics, and home care, drawing on interventions such as parenteral nutrition, enteral nutrition, and pharmacotherapy. Recent market insights indicate that growth is primarily driven by increasing awareness of the syndrome, advancements in genetic research, and emerging drugs approved by regulatory bodies like the FDA. Furthermore, an increasing prevalence of related conditions such as Crohn's disease also contributes to market expansion. Potential opportunities lie within the development of novel treatment modalities, enhancing absorption capabilities and improving quality of life for patients, particularly focusing on non-invasive treatment avenues and personalized medicine strategies. However, market growth is challenged by factors such as the high cost of treatment, limited availability of resources in low-income regions, and stringent regulatory approvals. Challenges also include potential side effects of existing treatments, which necessitates considerable innovation and research, particularly in optimizing drug formulations and delivery methods. Exploring biotechnological advancements, for instance, in gut microbiome therapies, offers promising avenues for addressing these challenges. The market nature symbolizes a competitive yet innovative landscape, with continuous R&D as pivotal for breakthroughs. To capitalize on these opportunities, businesses should prioritize collaborative initiatives with research institutions, invest in cutting-edge technologies, and foster personalized medicine approaches to cater to diverse patient needs effectively.
Understanding Market Dynamics in the Short Bowel Syndrome Market
The Short Bowel Syndrome Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.- Market Drivers
- Increased Prevalence of Short Bowel Syndrome and Awareness Programs
- Rising Efforts in the Launch of Effective Treatments
- Market Restraints
- Lack of Approved Treatment Options and Associated Adverse Complications with Drugs
- Market Opportunities
- Development of Short Bowel Syndrome Drugs is at a Nascent Stage
- Public-Private Partnerships are Encouraging Pharmaceutical Companies to Develop New Orphan Drugs for Short Bowel Syndrome
- Market Challenges
- Limited Initial Diagnostic and Availability of Advanced Option
Exploring Porter’s Five Forces for the Short Bowel Syndrome Market
Porter’s Five Forces framework further strengthens the insights of the Short Bowel Syndrome Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.Applying PESTLE Analysis to the Short Bowel Syndrome Market
External macro-environmental factors deeply influence the performance of the Short Bowel Syndrome Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.Analyzing Market Share in the Short Bowel Syndrome Market
The Short Bowel Syndrome Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.Evaluating Vendor Success with the FPNV Positioning Matrix in the Short Bowel Syndrome Market
The Short Bowel Syndrome Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.Strategic Recommendations for Success in the Short Bowel Syndrome Market
The Short Bowel Syndrome Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.Key Company Profiles
The report delves into recent significant developments in the Short Bowel Syndrome Market, highlighting leading vendors and their innovative profiles. These include 9 Meters Biopharma, Inc., Adocia SAS, Ardelyx Inc., AstraZeneca PLC, Emmaus Life Sciences, Inc., Merck KGaA, Nestlé S.A., Novartis International AG, OPKO Health, Inc., Oxthera AB, Pfizer Inc., PhaseBio Pharmaceuticals Inc., Sancilio and Company, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., VectivBio AG, Viatris Inc., and Zealand Pharma A/S.Market Segmentation & Coverage
This research report categorizes the Short Bowel Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:- Drug Class
- GLP-2
- Glutamine
- Growth Hormone
- Distribution Channel
- Hospital Pharmacies
- Online Sales
- Retail Pharmacies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report provides a detailed overview of the market, exploring several key areas:
- Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
- Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
- Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
- Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
- Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current size of the market, and how is it expected to grow?
- Which products, segments, and regions present the most attractive investment opportunities?
- What are the prevailing technology trends and regulatory factors influencing the market?
- How do top vendors rank regarding market share and competitive positioning?
- What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Short Bowel Syndrome Market, by Drug Class
7. Short Bowel Syndrome Market, by Distribution Channel
8. Americas Short Bowel Syndrome Market
9. Asia-Pacific Short Bowel Syndrome Market
10. Europe, Middle East & Africa Short Bowel Syndrome Market
11. Competitive Landscape
LIST OF FIGURES
LIST OF TABLES
Companies Mentioned
The leading players in the Short Bowel Syndrome market, which are profiled in this report, include:- 9 Meters Biopharma, Inc.
- Adocia SAS
- Ardelyx Inc.
- AstraZeneca PLC
- Emmaus Life Sciences, Inc.
- Merck KGaA
- Nestlé S.A.
- Novartis International AG
- OPKO Health, Inc.
- Oxthera AB
- Pfizer Inc.
- PhaseBio Pharmaceuticals Inc.
- Sancilio and Company, Inc.
- Swedish Orphan Biovitrum AB
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- VectivBio AG
- Viatris Inc.
- Zealand Pharma A/S
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 182 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 966.42 Million |
| Forecasted Market Value ( USD | $ 2780 Million |
| Compound Annual Growth Rate | 19.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
